Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
Authors
Keywords
Colorectal cancer, BRAF V600E mutation, KRAS mutations, Survival analysis, Stratified analysis
Journal
BMC CANCER
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-09-27
DOI
10.1186/1471-2407-13-439
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
- (2012) Reetesh K. Pai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer
- (2012) JiaoJiao Ren et al. DISEASES OF THE COLON & RECTUM
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
- (2010) S. Tejpar et al. ONCOLOGIST
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Basis of Colorectal Cancer
- (2009) Sanford D. Markowitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype
- (2008) D. R. English et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample
- (2008) Katsuhiko Nosho et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started